Phase 4 N=19 Plaque Psoriasis Study in Pediatric Subjects
Plaque Psoriasis
Primary: Success of Investigator's Global Assessment (IGA) — 3; 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=213 SCI-VIP: Predictive Outcome Model Over Time for Employment (PrOMOTE)
Spinal Cord Injuries
Primary: Identify Factors That Predict Employment After SCI. — 3.56 Odds Ratio
N/A N=50 Local Injection of Local Anesthetic 24 Hours After Knee Replacement Surgery May Decrease Pain for Several More Hours
Arthroplasty, Knee · Pain
Primary: Pain Assessed Using the VAS 0-10 Pain Scale — 2.763; 2.483 units on a scale
Phase 2 N=78 N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
Diabetic Nephropathy · Proteinuria · Oxidative Stress
Primary: Change From Baseline in Urinary Albumin Excretion — 50.5; -28.13; -4.5; 96.6 mg/g
N/A N=11 Electromyography in Patients on Chronic Pyridostigmine Therapy
Muscle Weakness
Primary: Percent Change in the Amplitude of Evoked Compound Muscle Action Potential by Electromyography Between the First to Fifth Response — 0 percent change
Phase 4 N=915 Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Rheumatoid Arthritis
Primary: Percentage of Subjects Who Met the American College of Rheumatology 20 % (ACR20) Criteria at Week 12 — 69.2; 71.4 Percentage of subjects — p==0.467
Phase 2 N=51 Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early…
N/A N=136 Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors
Tobacco Addiction · Dual Tobacco Use
Primary: Number of Days Using Alternative Products — 14; 26; 20 Number of days
Phase 3 N=34 Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Primary: Change in Mean Serum Copeptin From Baseline (a Reflection of Endogenous Vasopressin Production) at Week 2 — -0.86; 0.39 pmole/L — p=<0.01
Phase 4 N=11 An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder
Bipolar Disorder
Primary: Number of Participants With Serious Adverse Events (SAEs) — 0 Participants
N/A N=88 Clinical Utility of ERCP Guided Cholangiopancreatoscopy With the SpyGlass DS
Biliary Tract Disease
Primary: Number of Participants With Procedure Technical Success — 70; 3 participants
Phase 2 N=17 Effect of Desipramine on Genioglossus Muscle Activity in Healthy Adults Study A
Sleep Apnea, Obstructive
Primary: Genioglossus Activity During Non-rapid Eye Movement (NREM) Sleep Measured as Percent of Wakefulness Activity — 96; 75; 84; 93 percent wakefulness — p=0.01
Phase 2 N=52 Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Breast Cancer
Primary: Objective Response Rate — 71.2 Percentage of participants
Phase 2 N=69 Thiamine as an Adjunctive Therapy in Cardiac Surgery
Coronary Artery Bypass · Cardiac Surgical Procedures
Primary: Lactate Levels — 2; 2.0 mmol/L
Phase 3 N=72 Two Contrasting Interventions for Sleep Management
Primary Insomnia · Secondary Insomnia
Primary: Change in Subjective Measures of Sleep Using Medical Outcomes Study -Sleep Scale, From Baseline at 1-week Follow-up — 15.8; 16.1 units on a scale — p=0.84